These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

681 related items for PubMed ID: 28536078

  • 1. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
    Wang H, Quan H, Lou L.
    Biochem Biophys Res Commun; 2017 Jul 15; 489(1):14-20. PubMed ID: 28536078
    [Abstract] [Full Text] [Related]

  • 2. BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma.
    Dizdar L, Werner TA, Drusenheimer JC, Möhlendick B, Raba K, Boeck I, Anlauf M, Schott M, Göring W, Esposito I, Stoecklein NH, Knoefel WT, Krieg A.
    Int J Cancer; 2019 Mar 15; 144(6):1379-1390. PubMed ID: 30144031
    [Abstract] [Full Text] [Related]

  • 3. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF.
    Oncotarget; 2017 Feb 07; 8(6):9251-9266. PubMed ID: 27999210
    [Abstract] [Full Text] [Related]

  • 4. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, Ribas A.
    Sci Transl Med; 2015 Mar 18; 7(279):279ra41. PubMed ID: 25787767
    [Abstract] [Full Text] [Related]

  • 5. BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells.
    Wu Z, Huang M, Gong Y, Lin C, Guo W.
    Acta Biochim Biophys Sin (Shanghai); 2018 Apr 01; 50(4):355-361. PubMed ID: 29534162
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y, Xin BT, Zhang Y, Wu J, Lu X, Zheng Y, Tang W, Zhou X.
    Eur J Med Chem; 2015 Jan 27; 90():170-83. PubMed ID: 25461318
    [Abstract] [Full Text] [Related]

  • 7. Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.
    Hirschi B, Gallmeier E, Ziesch A, Marschall M, Kolligs FT.
    Mol Cancer; 2014 May 24; 13():122. PubMed ID: 24885690
    [Abstract] [Full Text] [Related]

  • 8. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M, Müller S, Britten M, Worm K, Schmid KW, Mann K, Fuhrer D.
    BMC Cancer; 2015 Mar 26; 15():184. PubMed ID: 25879531
    [Abstract] [Full Text] [Related]

  • 9. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
    Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S.
    J Clin Oncol; 2015 Dec 01; 33(34):4023-31. PubMed ID: 26392102
    [Abstract] [Full Text] [Related]

  • 10. TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel.
    Tan J, Liu R, Zhu G, Umbricht CB, Xing M.
    Proc Natl Acad Sci U S A; 2020 Jul 07; 117(27):15846-15851. PubMed ID: 32561648
    [Abstract] [Full Text] [Related]

  • 11. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.
    Hiraide S, Takahashi M, Yoshida Y, Yamada H, Komine K, Ishioka C.
    Cancer Sci; 2021 Sep 07; 112(9):3856-3870. PubMed ID: 34288281
    [Abstract] [Full Text] [Related]

  • 12. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.
    J Clin Oncol; 2008 Dec 10; 26(35):5705-12. PubMed ID: 19001320
    [Abstract] [Full Text] [Related]

  • 13. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH, Lee SE, Kim DW, Ryu MJ, Kim SJ, Kim SJ, Kim YK, Park JH, Kweon GR, Kim JM, Lee JU, De Falco V, Jo YS, Shong M.
    J Clin Endocrinol Metab; 2011 Jan 10; 96(1):E19-30. PubMed ID: 20926530
    [Abstract] [Full Text] [Related]

  • 14. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Pal HC, Baxter RD, Hunt KM, Agarwal J, Elmets CA, Athar M, Afaq F.
    Oncotarget; 2015 Sep 29; 6(29):28296-311. PubMed ID: 26299806
    [Abstract] [Full Text] [Related]

  • 15. Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors.
    Chatelle CV, Hövermann D, Müller A, Wagner HJ, Weber W, Radziwill G.
    Sci Rep; 2016 Mar 30; 6():23713. PubMed ID: 27025703
    [Abstract] [Full Text] [Related]

  • 16. BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma.
    Walter L, Heinzerling L.
    Anticancer Res; 2018 Mar 30; 38(3):1335-1341. PubMed ID: 29491057
    [Abstract] [Full Text] [Related]

  • 17. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F.
    Int J Cancer; 2013 Nov 30; 133(9):2089-101. PubMed ID: 23629727
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
    Del Curatolo A, Conciatori F, Cesta Incani U, Bazzichetto C, Falcone I, Corbo V, D'Agosto S, Eramo A, Sette G, Sperduti I, De Luca T, Marabese M, Shirasawa S, De Maria R, Scarpa A, Broggini M, Del Bufalo D, Cognetti F, Milella M, Ciuffreda L.
    J Exp Clin Cancer Res; 2018 Jul 09; 37(1):140. PubMed ID: 29986755
    [Abstract] [Full Text] [Related]

  • 19. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.
    King AJ, Arnone MR, Bleam MR, Moss KG, Yang J, Fedorowicz KE, Smitheman KN, Erhardt JA, Hughes-Earle A, Kane-Carson LS, Sinnamon RH, Qi H, Rheault TR, Uehling DE, Laquerre SG.
    PLoS One; 2013 Jul 09; 8(7):e67583. PubMed ID: 23844038
    [Abstract] [Full Text] [Related]

  • 20. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
    Caporali S, Alvino E, Lacal PM, Levati L, Giurato G, Memoli D, Caprini E, Antonini Cappellini GC, D'Atri S.
    Int J Oncol; 2016 Sep 09; 49(3):1164-74. PubMed ID: 27572607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.